Jones B M, Lau C S, Wong R W
Department of Pathology, University of Hong Kong, Queen Mary Hospital.
Autoimmunity. 1994;18(3):189-94. doi: 10.3109/08916939409007995.
While attempting to evaluate CD5+ and CD5- anti-DNA-secreting plaque-forming cells (PFC) in patients with systemic lupus erythematosus (SLE), significant numbers of PFC against control sheep erythrocytes (ShE) treated with poly-L-lysine (PLL) but not further conjugated with single-stranded (ss) or double-stranded (ds) DNA were noted. Numbers of PFC obtained using PLL-ShE, ssDNA-ShE and dsDNA-ShE were not significantly different, all reactivity to DNA apparently being accounted for by binding of antibodies to PLL-treated ShE. Nevertheless, anti-PLL-PFC could be inhibited by soluble dsDNA included in the plaque assay. These findings might be explained by cationic anti-DNA antibodies binding non-specifically to anionic PLL. Control healthy subjects gave few PFC against PLL-ShE, ssDNA-ShE or dsDNA-ShE. Anti-PLL-PFC appeared to be related to disease activity, with higher numbers of both CD5+ and CD5- PFC in patients with clinically active SLE.
在试图评估系统性红斑狼疮（SLE）患者中CD5 +和CD5 -抗DNA分泌性噬斑形成细胞（PFC）时，发现大量针对用聚-L-赖氨酸（PLL）处理但未进一步与单链（ss）或双链（ds）DNA偶联的对照绵羊红细胞（ShE）的PFC。使用PLL-ShE、ssDNA-ShE和dsDNA-ShE获得的PFC数量无显著差异，所有对DNA的反应性显然是由抗体与PLL处理的ShE结合引起的。然而，噬斑试验中包含的可溶性dsDNA可抑制抗PLL-PFC。这些发现可能是由于阳离子抗DNA抗体与阴离子PLL非特异性结合所致。对照健康受试者针对PLL-ShE、ssDNA-ShE或dsDNA-ShE产生的PFC很少。抗PLL-PFC似乎与疾病活动有关，临床活动期SLE患者中CD5 +和CD5 - PFC的数量均较多。
